• Journal of Veterinary Clinics
• /
• v.11 no.1
• /
• pp.359-368
• /
• 1994

This study was undertaken to evaluate image quality and level of discomfort during examination with various contrast media(meglumine ioxitalamate: Telebrix $30^{\circledR}$ , diatrizoate sodium: Hypaque $50^{\circledR}$, sodium ioxaglate ＋ meglumine ioxaglate: Hexabrix , iopamidol: Iopamiro $300^{\circledR}$ , iodized poppyseed oil: $Lipiodol^{\circledR}$ and barium sulfate: Baritop$^{\circledR}$and various radiographic contrast techniques(eye dropping: group 1, single injection to the superior punctum: group 2 and continuous injection to the superior punctum: group 3) on dacryocystorhinography in dogs. The results were as follows; 1. The Image quality of radiographic contrast technique of continuous Injection of contrast media(group 3) was better than the other techniques. 2. Average scores for dacryocystorhinography quality of sodium ioxaglate ＋ meglumine ioxaglate, iopamidol, barium sulfate, iodized Poppyseed oil, meglumine ioxitalamate and diatrizoats sodium were 3.67${\pm}$0.47, 3.67${\pm}$0.47, 3.50${\pm}$0.50, 3.33${\pm}$0.75, 2.50${\pm}$0.50 and 2.50${\pm}$0.76, respectively in group 3. 3. Diatrizoate sodium produced more discomfort than the other media. It was considered that the best radiographic contrast technique of dacryocystorhinography was continuous injection of contrast media to the superior punctum and sodium ioxaglate + meglumine ioxaglate, iopamidol, iodized Poppyseed oil and barium sulfate were the excellent contrast media for dacryocystorhinography in dogs.

• Journal of Trauma and Injury
• /
• v.18 no.2
• /
• pp.112-118
• /
• 2005

Background: N-Butyl Cyanoacrylate (NBCA) is a liquid embolic material that can be useful for transcatheter arterial embolization (TAE) of acute bleeding especially in patients with coagulopathy, because it does not depend on coagulation for its therapeutic effect. The aims of this study were to evaluate the clinical efficacy and safety of TAE with NBCA in acute bleeding patients. Methods: Between August 2003 and September 2004, TAE using NBCA for acute bleeding was performed in 23 patients (16 men, 7 women; mean age, 56.5years). The causes of bleeding were gastric ulcer (n=5), postoperative bleeding (n=4), post-biopsy bleeding (n=3), postpartum bleeding (n=3), duodenal ulcer (n=2), angiodysplasia (n=2), gastric lymphoma (n=1), iatrogenic injury (n=1), CMV gastritis (n=1), stab injury of the liver (n=1). TAE was performed using 1:3 mixtures of NBCA and iodized oil. The angiographic and clinical success rate, recurrent bleeding rate, procedure-related complication and clinical outcomes were evaluated. Results: The angiographic and clinical success rate was 100% and 91.3% (21/23), respectively. There was no serious ischemic complication. Recurrent bleeding occurred in 2 patients (8.7%) and they were managed with successful second TAE (n=1) and endoscopic treatment (n=1). Nine patients (39.1%) had coagulopathy at the time of TAE and clinical success rate in this group of patients was 88.9% (8/9). Conclusions: TAE with NBCA is highly effective and safe treatment modality for acute bleeding patients, especially when the patient has a coagulopathy.

• The Korean Journal of Nuclear Medicine
• /
• v.20 no.2
• /
• pp.61-71
• /
• 1986

An iodized oil such as Ethiodol or Lipiodol was selectively retained in the tumor vessels of the large hepatomas as well as in the small daughter hepatomas for long periods following the intra-arterial hepatic injection of such contrast material. The specific aim of the study is to deliver a high internal radiation dose to hepatocellular carcinoma (HCC) in an attempt to control the disease. We were able to replace a small fraction of the stable iodine (I-127) of the 37% iodine in Lipiodol by the $I^{-131}$ with 100% exchange efficiency. $I^{-131}$ labeled Lipiodol was injected through the super-selected tumor feeding artery under superselection or into the proper hepatic arterial level of patients who have malignant hepatomas confirmed by aspiration cytology serum AFP and various imaging modalities. Clinical traial was performed on 43 cases during recent 6 months and follow-up observation was carried out. No severe complications or other adverse reactions were encountered until nowdays. $I^{-131}-Lipiodol$ was stable in vivo and no significant activity was noted in the thyroid, stomach, blood and urine after the injection. Only small fraction of radioisotope activity was noticed in the both side of lungs. Tumor to normal liver radio was very high. Therefore, $I^{-131}-Lipiodol$ (or P-32-Lipiodol) will be effective delivering high internal radiation dose to the tumor while delivering small radiation doses to normal tissues. Labeling, tumor dose calculation and preliminary findings will be presented.

• Korean Journal of Radiology
• /
• v.19 no.6
• /
• pp.1130-1139
• /
• 2018

Objective: To compare the therapeutic efficacy between conventional transarterial chemoembolization (cTACE) and combined therapy using cTACE and radiofrequency ablation (RFA) in ultrasound (US)-invisible early stage hepatocellular carcinoma (HCC). Materials and Methods: From January 2008 to June 2016, 167 patients with US-invisible early stage HCCs were treated with cTACE alone (cTACE group; n = 85) or cTACE followed by immediate fluoroscopy-guided RFA targeting intratumoral iodized oil retention (combined group; n = 82). Procedure-related complications, local tumor progression (LTP), time to progression (TTP), and overall survival (OS) were compared between the two groups. Multivariate analyses were performed to identify prognostic factors. Results: There was no major complication in either group. The cTACE group showed higher 1-, 3-, and 5-year LTP rates than the combined group; i.e., 12.5%, 31.7%, and 37.0%, respectively, in the cTACE group; compared to 7.3%, 16.5%, and 16.5%, respectively, in the combined group; p = 0.013. The median TTP was 18 months in the cTACE group and 24 months in the combined group (p = 0.037). Cumulative 1-, 3-, and 5-year OS rates were 100%, 93.2%, and 87.7%, respectively, in the cTACE group and 100%, 96.6%, and 87.4%, respectively, in the combined group (p = 0.686). Tumor diameter > 20 mm and cTACE monotherapy were independent risk factors for LTP and TTP. Conclusion: Combined therapy using cTACE followed by fluoroscopy-guided RFA is a safe and effective treatment in US-invisible early stage HCCs. It provides less LTP and longer TTP than cTACE alone.